Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", 80131 Naples, Italy.
U.O.C. Clinica Pneumologica "L. Vanvitelli", A.O. dei Colli, Ospedale Monaldi, 80131 Naples, Italy.
Molecules. 2022 Dec 15;27(24):8919. doi: 10.3390/molecules27248919.
COVID-19 is an infective disease resulting in widespread respiratory and non-respiratory symptoms prompted by SARS-CoV-2 infection. Interaction between SARS-CoV-2 and host cell receptors prompts activation of pro-inflammatory pathways which are involved in epithelial and endothelial damage mechanisms even after viral clearance. Since inflammation has been recognized as a critical step in COVID-19, anti-inflammatory therapies, including both steroids and non-steroids as well as cytokine inhibitors, have been proposed. Early treatment of COVID-19 has the potential to affect the clinical course of the disease regardless of underlying comorbid conditions. Non-steroidal anti-inflammatory drugs (NSAIDs), which are widely used for symptomatic relief of upper airway infections, became the mainstay of early phase treatment of COVID-19. In this review, we discuss the current evidence for using NSAIDs in early phases of SARS-CoV-2 infection with focus on ketoprofen lysine salt based on its pharmacodynamic and pharmacokinetic features.
COVID-19 是一种传染病，由 SARS-CoV-2 感染引起广泛的呼吸道和非呼吸道症状。SARS-CoV-2 与宿主细胞受体的相互作用促使促炎途径激活，即使在病毒清除后，这些途径也参与上皮和内皮损伤机制。由于炎症已被认为是 COVID-19 的关键步骤，因此已提出抗炎治疗，包括类固醇和非类固醇以及细胞因子抑制剂。COVID-19 的早期治疗有可能影响疾病的临床过程，而与潜在的合并症无关。广泛用于缓解上呼吸道感染症状的非甾体抗炎药（NSAIDs）已成为 COVID-19 早期治疗的主要药物。在这篇综述中，我们讨论了 NSAIDs 在 SARS-CoV-2 感染早期阶段的使用的现有证据，重点是基于其药效学和药代动力学特征的酮咯酸赖氨酸盐。
